Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine

1

Rimegepant is approved for both acute treatment and prevention of migraines, addressing a significant need in migraine management.
2

The meta-analysis included 5 trials with 2,715 subjects receiving rimegepant and 2,850 in the control group, demonstrating its effectiveness.
3

Rimegepant significantly alleviated pain and relieved the Most Bothersome Symptom within 2 hours post-treatment compared to placebo.
4

The medication did not show significant efficacy in preventing pain recurrence from 2 to 48 hours after administration.
5

Rimegepant was generally well tolerated, with no significant difference in adverse events compared to the control group.

1